Sandoz to Engage With U.S. Policymakers After Trump's Tariff Plan
By Adria Calatayud
Sandoz Group said it would engage with U.S. policymakers after President Trump announced a 100% tariff on generic drugs from 2028, but that it is too early to assess how the plan will affect its manufacturing or investments.
Trump posted on social media Tuesday that he would give manufacturers of generic drugs time to move facilities to the U.S. before putting in place a 100% tariff starting in August 2028.
In response, Swiss generic-drug maker Sandoz said Wednesday that further details on the scope and implementation of the measure are still required before it can assess its potential implications.
"We share the goal of improving affordability and access to medicines in the United States," a Sandoz spokesman said. "We look forward to continuing our dialogue with policymakers on how best to achieve these shared objectives."
The company said generics and biosimilars--copycat biologic drugs--already contribute to lowering healthcare costs and broaden access to treatment for patients.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
July 22, 2026 02:02 ET (06:02 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States